e-learning
resources
Paris 2018
Sunday, 16.09.2018
Primary care management of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
REducing Delay through edUcation on eXacerbations (REDUX) in patients with COPD
C. Hallensleben (Leiden, Netherlands), J. Biewenga (Leiden, Netherlands), J. van Boven (Groningen, Netherlands), N. Chavannes (Leiden, Netherlands)
Source:
International Congress 2018 – Primary care management of COPD
Session:
Primary care management of COPD
Session type:
Thematic Poster
Number:
919
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Hallensleben (Leiden, Netherlands), J. Biewenga (Leiden, Netherlands), J. van Boven (Groningen, Netherlands), N. Chavannes (Leiden, Netherlands). REducing Delay through edUcation on eXacerbations (REDUX) in patients with COPD. 919
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD
Source: International Congress 2015 – Different data in COPD
Year: 2015
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
The severity of anxiety in COPD patients (pts)
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Non invasive ventilation (NIV) in COPD exacerbation (AECOPD) in elderly patients
Source: Annual Congress 2010 - Noninvasive ventilation in the acute patient: outcome and pathophysiology
Year: 2010
PP307 – The role of microalbuminuria (MAB) in patients admitted for an Acute COPD Exacerbation (AECOPD)
Source: ERS Lung Science Conference 2021
Year: 2021
Outcomes in patients with COPD during a 3 year follow-up
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Mental disorders in patients (pts) with COVID-19 pneumonia:comparison with COPD exacerbation
Source: Virtual Congress 2021 – Long COVID - 19
Year: 2021
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
COPD Assessment Test (CAT) has a positive relationship with exacerbations in COPD patients.
Source: International Congress 2019 – Clinical implications of COPD management
Year: 2019
Impulse-oscillometry (IOS) differences in asthma and COPD patients, and healthy-subjects
Source: International Congress 2014 – Airways: reversibility and responsiveness
Year: 2014
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept